Published Results

1) Stevenson WC, Sawyer RG, Pruett TL: Recurrent variceal bleeding after liver transplantation - persistent left-sided portal hypertension. Transplantation, 1992;53:493-5.
2) Rosenlof LK, Earnhardt MD, Pruett TL, Stevenson WC, Douglas MT, Cornett BS, Hanks JB: Pancreas transplantation: An initial experience with systemic and portal drainage of pancreatic allografts. Ann of Surg, 1992;215:586-96.
3) Lobo PI, Spencer C, Douglas MT, Stevenson WC, Pruett TL: The lack of long-term detrimental effects on liver allografts caused by donor-specific anti-HLA antibodies. Transplantation, 1993;55:1063-6.
4) Xu HS, Pruett TL, Jones RS: Study of donor-recipient liver size match for transplantation. Ann of Surg, 1994;219:46-50.
5) Xu HS, Rosenlof LK, Pruett TL, Jones RS: Prostaglandin E1 increases survival with Extended anhepatic phase during liver transplantation. Ann Surg, 1994;220:53-8.
6) Sawyer RG, Pruett TL: Wound infections. Surg Clin N Amer, 1994;74(3):519-36.
7) Kiyasu PK, Ishitani MB, McGory RW, Gaffey MJ, Dickson RC, Caldwell SH, Stevenson WC, Pruett TL: Prevention of Hepatitis B "Re-recurrence" after second liver transplant - role of maintenance polyclonal HBIG therapy. Transplantation, 1994;58:954-6.
8) Lobo PI, Spencer CEW, Stevenson WC, Pruett TL: Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor specific lymphocytotoxin. Transplantation, 1995;59:357-60.
9) Sawyer RG, Durbin CG, Rosenlof LK, Pruett TL: Comparison of APACHE II scoring in liver and kidney transplant recipients vs. trauma and general surgical patients. Clin Transplantation, 1995;9:401-5.
10) Stevenson WC, Gaffey MJ, Ishitani MB, McCullough C, Dickson R, Caldwell S, Lobo P, Pruett T: Clinical course of four patients receiving the experimental antiviral Fialuridine for the treatment of chronic hepatitis B infection. Tran Proc, 1995;27:1219-21.
11) McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka JF, Straus SE, Hoofnagle JH: Hepatic failure and lactic acidosis due to Fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Eng J of Med 1995;333(17):1099-1105.
12) Lobo PI, Spencer CI, Stevenson WC, Pruett TL: The use of pronase-digested human leukocytes to improve specificity of the flow cytometric cross-match. Transp Int 1995;8:472-80.
13) Lobo PI, Cortez MS, Stevenson W, Pruett TL: Normocalcemic hyperparathyroidism associated with relatively low 1:25 vitamin D levels post-renal transplant can be successfully treated with oral calcitriol. Clin Transplantation 1995;9:277-281.
14) McGory R, Ishitani M, Oliveira W, Stevenson W, Dickson R, Caldwell S, Pruett T. The effects of Fialuridine (FIAU) on HBIG pharmacokinetics following OLT in patients with chronic HBV infection. Transplantation 1995;27(1):1213-14.
15) McKenzie R, Fried MW, Sallie R, Conjeevaram H, DiBisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka J, Straus SE, Hoofnagle JH. Hepatic failure and lactic acidosis: severe multi-system toxicity from FIAU, an antiviral therapy for chronic hepatitis B. N Engl J Med 1995;333:1099-1105.
16) Barone G, Burke CM, Choc MG Jr, Hricik DE, Jin J H-J, Klein JB, Marsh CL, Min DI, Pescovitz MD, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL (The Neoral Study Group): Safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. Transplantation 1996;61(6):968-987.
17) Barone G, Chang CT, Choc MG Jr, Klein JB, Marsh CL, Meligeni JA, Min DI, Pescovitz MD, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL (The Neoral Study Group): The pharmacokinetics of a microemulsion formulation of cyclosporin Neoral in primary renal allograft recipients. Transplantation 1996;61(6):875-880.
18) Dickson, RC, Caldwell SH, Ishitani MB, Lau JYN, Driscoll CJ, Stevenson WC, McCullough CS, Pruett TL: Clinical and histologic patterns of early graft failure due to the recurrent hepatitis C in four patients after liver transplantation. Transplantation 1996;61(5):701-705.
19) Caldwell SH, Sue M, Bowden JH, Dickson RC, Driscoll CJ, Yeaton P, Stevenson WC, Ishitani MB, McCullough CS, Pruett TL, Lovell MA: Hepatitis C virus in body fluids after liver transplantation. Liver Trans & Surg 1996;2(2):124-129.
20) Blumberg EA, Albano C, Pruett T, Isaacs R, Fitzpatrick J, Bergin J, Crump C, Hayden FG: The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996;22:295-302.
21) McGory R, Ishitani M, Oliveira W, Stevenson W, McCullough C, Dickson R, Caldwell S, Pruett T. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61(9):1358-1364.
22) Klein AS, Cofer JB, Pruett TL, Thuluvath PQ, McGory R, Uber L, Stevenson WC, Baliga P, Burdick JF (The SEOPF Liver Transplant Study Group): Prostaglandin E1 administration following orthotopic liver transplantation: a randomized prospective multicenter trial. Gastroenterol 1996;111:710-715.
23) Caldwell SH, deLange EE, Gaffey MJ, Dickson RC, Sue M, Driscoll C, Stevenson WC, Ishitani MB, McCullough C, Pruett TL. Accuracy and significance of pre-transplant liver volume measured by magnetic resonance imaging. Liver Trans & Surg 1996;2(6)438-442.
24) Al-Hemsi B, McGory RW, Shepard B, Ishitani MB, Stevenson WC, McCullough C, Pruett TL. Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization. Clin Transplantation 1996;10:668-675.
25) Pankewycz OG, Miao L, Guan J, Isaacs R, Pruett T, Haussman G, Sturgill BC. Increased renal tubular expression of transforming growth factor beta in human allografts correlated with cyclosporine toxicity. Accepted for publication in Kidney Int 1996;50:1-7.
26) Gaffey MJ, Boyd JC, Traweek ST, Ali MA, Rezeig M, Caldwell SH, Iezzoni JC, McCullough C, Stevenson WC, Khuroo S, Nezamuddin N, Ishitani MB, Pruett TL. Predictive value of intraoperative biopsies and liver function tests for preservation injury in orthotopic liver transplantation. Hepatology 1997;25:184-189.
27) Sanfey H, Haussman G, Isaacs I, Ishitani M, Lobo P, McCullough C, Pruett T. Steroid withdrawal in kidney transplant recipients: Is it a safe option? Clin Transplant 1997;11(5 pt 2):500-504
28) Pescovitz MD, Barone G, Choc, JR. MG, Hricik DE, Hwang DS, Jin JHJ, Klein JB, Marsh CL, Min DI, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL. Safety and tolerability of cyclosporine microemulsion vs. cyclosporine: two-year data in primary renal allograft recipients. Transplantation 1997;63:778-780.
29) Ishitani MB, McGory R, Dickson R, Caldwell S, Bickston S, McCullough C, Pruett T, Terrault N, Roberts J, Ascher N, Wright T, Lake J. Retransplantation of Patients with severe post-transplant Hepatitis B in the first allograft. Transplantation 1997;64:410-414.
30) Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, Zetterman RK, Pruett TL, Ishitani MB, Hoofnagle JH, and the NIDDK: Liver Transplantation Database: Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997;113(5):1668-1674.
31) Caldwell SH, Ishitani MB, Gaffey MJ, Shepard BL, McGory RW, Pruett TL. The significance of isolated pre-transplant hepatitis B anti-core antibody. Trans Proc 1997;29(7):2846-2847.
32) Gane E, Saliba F, Valdecasas G, O'Grady J, Behrend M, Pescovitz MD, Pruett T, Hockerstedt K, Fischer L, Mino-Fugarolas G, Houssin D, Davis C, Henry M, Erhard J, Kam I, Walker MG, Lyman S, King P, Robinson CA. Efficacy and safety of oral ganciclovir in the prevention of CMV disease in liver transplant recipients. Lancet 1997;350:1729-1733.
33) Dickson RC, Wright RM, Bacchetta MD, Bodily SE, Caldwell SH, Driscoll CJ, Pruett TL, Ishitani MB. The quality of life of Hepatitis B and C patients after liver transplantation. Clin Transplant 1997;11(4):282-285.
34) Pruett T. Primary transplant treatment of hepatitis B: HBIG (passive immunization). Liver Transpl Surg 1997;3(5 suppl 1):S13-S15 review.
35) Pruett TL. Editorial Response: De novo HBV infections after liver transplantation. Liver Transpl Surg; 1998 Mar;4(2):182-184.
36) Sawyer RG, McGory RW, Gaffey MJ, McCullough CS, Shephard B, Houlgrave CW, Ryan TS, Kuhns M, McNamra A, Caldwell SH, Abdulkareem A, Pruett TL. Improved clinical outcomes with liver transplantation for hepatitis B induced chronic liver failure using passive immunization. Ann Surg 1998;227(6):841-850.
37) McCune TR, Thacker LR II, Peters TG, Mulloy L, Rohr MS, Adams PA, Yium J, Light JA, Pruett T, Gaber AO, Selman SH, Jonsson J, Hayes JM, Wright FH Jr, Armata T, Blanton J, Burdick JF. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation 1998;65(1):87-92.
38) Terrault NA, Zhou S, McGory RW, Pruett TL, Lake JR, Roberts JP, Ascher NL, Wright TL. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin . Hepatology 1998;28(2):555-561.
39) Sawyer RG, Pelletier SJ, Pruett TL. Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. Clin Transplantation 1999: 13:127-131.
40) Marsh CL, Pescovitz MD, Wong RL, Barone G, Choc, Jr. MG, Hwang D-S, Klein JB, Min DI, Pollak R, Pruett TK, Stinson JB, Thompson JS, Vasquez, Waid T, Wombolt DG, Chang C-T. Abreviated Pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in De Novo renal transplant patients treated with Sandimmune or Neoral. Therapeutic Drug Monitoring 2/1999:21:27-34
41) Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 2000: 6(1):44-53.
42) Sawyer RG, Pelletier SJ, Spencer CE, Pruett TL, Isaacs RB. Increased late hepatic artery thrombosis rate and decreased graft survival after liver transplants with zero cross-reactive group (CREG) mismatches. Liver Transpl 2000: 6(2)229-36.
43) Oh CK, Sawyer RG, Pelletier SJ, McCullough C, Sanfey H, Pruett TL. Implication of advanced donor age on the outcome of liver transplantation. Clin Transplant, August 2000: 14: 386-390.
44) Pelletier SJ, Crabtree TD, Gleason TG, Raymond DP, Oh CK, Pruett TL, Sawyer RG. Characteristics of infectious complications associated with mortality after solid organ transplantation. Clin Transplant August 2000: 14: 401-408.
45) Pruett, TL. Advances in the treatment of recurrent hepatitis B after liver transplantation; an introduction to the supplement. Clin Transplantation, August 2000: 14 (Suppl. 2): 5-6.
46) Pruett, TL, McGory, R. Hepatitis B immune globulin: the US experience. Clin Transplantation, August 2000: 14 (Suppl 2): 7-13.
47) Pelletier SJ, Raymond DP, Crabtree TD, Iezzoni JC, Sawyer RG, Hahn YS, Pruett TL. Pre-transpalnt hepatitis C virus quasispecies may be predictive of outcome after liver transplantation. Hepatology August 2000: 32(2):375-38.
48) Pelletier SJ, Raymond DP, Crabtree TD, Berg CL, Iezzoni JC, Hahn YS, Sawyer RG, Pruett TL. Hepatitis C-induced hepatic allograft injury is associated with a pre-transplant elevated viral replication rate. Hepatology 2000: 32(2) 418-426.
49) Isaacs RB, Lobo PI, Nock SL, Hanson JA, AF, Ojo AO, Pruett TL. Racial disparities in access to simultaneous pancreas kidney transplantation in the United States. American Journal of Kidney Diseases, Vol 36, No3 September 2000.